Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (September 2019)

Friday, November 29, 2019

Between January and September 2019, Russia imported 98.3 bln RUB worth of APIs (customs clearance prices, VAT included), which is in monetary terms (rubles) 42% higher than that of the same period in 2018. This is the highest dynamics since the ruble devaluation in 2015, and the import volume of the first 9 months of 2019 exceeded the total import in 2018.

The import growth was in fact due to the price increase. The average prices of APIs has grown by 24% this year, to 10.3 thousand RUB for 1 kg. The import dynamics in physical terms (tons) are +14.4%, with 9.5 tons of APIs. While the dynamics are quite high, they are far from record-worthy.

The import structure and the currency used for paying for imports have experienced some changes this year. Between January and September 2019, 68% of the imports in monetary terms were paid for in rubles, against 64% in 2018. For example, only 10.5% was paid for in rubles in 2010, when the main currency was the US dollar, used for nearly 72% of the imports.

The import of commercial APIs has fallen by 10% in physical terms and has grown by 2.3 times in monetary terms. As for pharmacopoeial APIs, the import dynamics are +15% and +40% in in physical anf monetary terms, respectively.

The import line has grown from 723 to 765 API names. Russia stopped importing 120 APIs and started importing 162 new ones. Among the new APIs, Dolutegravir Natrium by Japanese Shionogi has the highest import volume. Russia started importing this API, used for manufacturing Tivicay by ViiV Healthcare, in February 2019. The production of Tivicay is localized at the facilities of the Russian plant belonging to French Servier in Troitsk. The total import volume amounts to 4.3 bln RUB (customs clearance price).

In the top 30 APIs, the import Dydrogesterone Granules (a 228 times increase) and Pantoprazole Sodium Sesquihydrate (a 215 times increase) showed the highest dynamics in monetary terms. Dydrogesterone Granules is imported from the Netherlands for the localized production of Abbott’s Duphaston at the facilities of Veropharm in Belgorod. Pantoprazole Sodium Sesquihydrate is primarily imported from Slovenia for the production of KRKA’s Nolpaza. Pantoprazole is also imported from Spain for Canonpharma Production and Protek-SVM and India for Akrikhin.

Dynamics of pharmacopoeial and commercial API import to Russia (imports from the EEU countries excluded), customs clearance prices (2016 – 2018, January – September 2019), bln RUB

Share: